Trustees of Columbia University in the City of New York Acquires New Holdings in Q32 Bio Inc. (NASDAQ:QTTB)

Trustees of Columbia University in the City of New York acquired a new stake in shares of Q32 Bio Inc. (NASDAQ:QTTB) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 133,903 shares of the company’s stock, valued at approximately $461,000. Q32 Bio makes up about 0.1% of Trustees of Columbia University in the City of New York’s portfolio, making the stock its 5th biggest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in QTTB. Barclays PLC raised its position in Q32 Bio by 105.2% during the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock valued at $465,000 after acquiring an additional 5,353 shares in the last quarter. Drive Wealth Management LLC bought a new position in Q32 Bio during the fourth quarter valued at approximately $38,000. Bleakley Financial Group LLC bought a new position in Q32 Bio during the fourth quarter valued at approximately $149,000. Savant Capital LLC bought a new position in Q32 Bio during the fourth quarter valued at approximately $53,000. Finally, Rhumbline Advisers raised its position in Q32 Bio by 1,164.3% during the fourth quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock valued at $363,000 after acquiring an additional 97,196 shares in the last quarter. Institutional investors own 31.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on QTTB. Piper Sandler lowered shares of Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $20.00 to $4.00 in a research report on Tuesday, February 11th. Wells Fargo & Company dropped their price target on shares of Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 12th. Finally, BMO Capital Markets lowered shares of Q32 Bio from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $22.00 to $3.00 in a research report on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.71.

Q32 Bio Trading Up 1.7%

NASDAQ:QTTB opened at $1.77 on Friday. Q32 Bio Inc. has a 12 month low of $1.38 and a 12 month high of $53.79. The firm has a market cap of $21.59 million, a price-to-earnings ratio of -0.12 and a beta of -0.02. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $1.79 and its 200-day moving average is $8.75.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.33. Equities analysts anticipate that Q32 Bio Inc. will post -12.32 EPS for the current year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.